Some studies suggested a positive influence of RASi on overall survival (OS) [14], [15], [16], some indicated a negative impact of RASi use on the risk of developing PCa [17], [18], while others showed no significant difference between RASi-treated patients and those who were RAS-naïve [19]. Here, MMP19 is linked to posterior cortical atrophy.